Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
Date:1/28/2010

by increased demand, partially offset by the unfavorable impact of foreign exchange rates.

Alimta

For the fourth quarter of 2009, Alimta generated sales of $523.6 million, an increase of 64 percent compared with the fourth quarter of 2008. U.S. sales of Alimta increased 42 percent, to $228.8 million, due to increased demand. Sales outside the U.S. increased 87 percent, to $294.8 million, due to increased demand and, to a lesser extent, the favorable impact of foreign exchange rates. Demand outside the U.S. was favorably impacted by the addition in mid-2009 of the non-small cell lung cancer indication in Japan.

For the full-year of 2009, worldwide Alimta sales increased 48 percent to $1.706 billion. U.S. Alimta sales for 2009 were $815.6 million, a 45 percent increase driven by higher demand. Alimta sales outside the U.S. were $890.4 million, a 50 percent increase driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates.

Cialis

Cialis sales for the fourth quarter of 2009 increased 19 percent compared with fourth-quarter 2008 to $439.5 million. U.S. sales of Cialis were $166.2 million in the fourth quarter, a 12 percent increase compared with the fourth quarter of 2008, driven primarily by higher prices. Sales of Cialis outside the U.S. increased 24 percent, to $273.4 million, driven by increased demand, higher prices and the favorable impact of foreign exchange rates.

For the full-year of 2009, worldwide Cialis sales increased 8 percent to $1.559 billion. U.S. Cialis sales for 2009 were $
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Tuesday, August 5, 2014 ... management will hold a conference call at 8:00 a.m. ... p.m., Beijing Time on August 6, 2014, to discuss ...
(Date:7/29/2014)... 29, 2014 , Next ... development program has commenced , TPM®/Oxycodone Phase ... during Q4 2014 , TPM®/Oxymorphone Phase 2 ... 1H 2015 Australian drug delivery company, Phosphagenics ... transdermal patch programs after its recent announcement of a $19.2 million ...
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first,natural compound to ... on stroke,recovery starting in the acute stage. ... trial to evaluate the efficacy of NeuroAid(TM) in ... with treatment starting within 48 hours of a ...
... 26 Rcadia Medical Imaging, Ltd.,developer of novel ... Food and Drug Administration (FDA) clearance to market,its ... triaging patients for,coronary artery disease (CAD). The new ... human intervention and automatic detection of,pathologies in the ...
Cached Medicine Technology:International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 2International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 3International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 4Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance 2
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... 29, 2014 Catalent Pharma Solutions, ... advanced delivery technologies for pharmaceutical, biologic, and consumer ... R&D Director and US Platform Leader of Pharmaceutical ... Drugs with Lipid-Based Formulations using Soft Capsule Delivery ... the Japan Society of Drug Delivery Systems (30-31 ...
(Date:7/29/2014)... The Affordable Care Act has created a dramatic ... show that over 400 hospitals probably won’t survive this ... that great hospitals use to survive the threat increases ... secret? Debriefing - the simple process of systematically offering ... operational event. Debriefing is a standard procedure in military ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter , MONDAY, ... three years longer than people who don,t run, according to new ... that it appears that you can reap this benefit even if ... 15-year study suggests. "People may not need to run ... an assistant professor of kinesiology at Iowa State University. "I hope ...
(Date:7/29/2014)... Kelly and Zhi Sheng , assistant professors ... recently received a grant from the Commonwealth Health ... effort that may lead to new treatment approaches. , ... , The grant will fund a two-year project to ... the BRCA1 gene. This type of cancer often has ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Running Could Add 3 Years to Your Lifespan 2Health News:Running Could Add 3 Years to Your Lifespan 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2
... Better ... Treatment Options, WASHINGTON, Nov. 2 Today, the ... for interventional cardiology, announced the,launch of Seconds Count, a ... an authoritative resource about cardiovascular disease and,treatment. The program ...
... AMED or the "Company"), one of America,s leading home ... and,Chief Operating Officer, and Dale E. Redman, Chief Financial ... Annual Healthcare Conference in,New York on Tuesday, November 6, ... Eastern time. The audio,presentation will be webcast live and ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... IDM Pharma, Inc.,(Nasdaq: IDMI ) today announced ... mifamurtide (L-MTP-PE) in patients,with lung metastases as a result ... bone tumor that typically affects children and young,adults. The ... is,safe, well-tolerated and exhibited signs of disease control. ...
... Medical,s blood loss detection,device for monitoring venous needle ... available for sale in the United States. The ... the world,s,first such device. Having met Europe,s rigorous ... granted CE approval. With the FDA,s approval,Redsense is ...
... Statement by James Wagoner on the $28 ... Nov. 1 The following is a,statement ... increase in abstinence-only,program funding:, Today, we ... committee report includes the full $28 million,increase ...
Cached Medicine News:Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3Health News:Amedisys to Present at 2007 CIBC Healthcare Conference in New York 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 2Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 4Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 6Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 7Health News:Redsense Medical Receives FDA Approval for Blood Loss Detection Device 2Health News:Redsense Medical Receives FDA Approval for Blood Loss Detection Device 3Health News:Democrats Cave on Sex Education - Again 2
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
... for screening donors on the PK7200 Automated ... CMV antigen attached to a gelatin particle ... and specificity of the CMV assay as ... respectively. The use of a gelatin particle ...
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
... designed for medium to ... centers and reference laboratories ... antibody screening. It will ... functions including blood group ...
Medicine Products: